Summary & Overview

HCPCS J7501: Azathioprine, Parenteral, 100 mg

HCPCS Level II code J7501 denotes azathioprine, parenteral, 100 mg, a systemic immunosuppressive medication administered by injection or infusion. This designation matters nationally because parenteral azathioprine is used in managing autoimmune conditions and transplant-related immunosuppression, and accurate coding affects clinical documentation, claim adjudication, and national drug utilization reporting.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on clinical context for parenteral azathioprine, common sites of service where this code is billed, and the billing landscape relevant to public and major commercial payers.

The publication provides benchmarks for use and reimbursement patterns where available, highlights payer coverage considerations and billing practice implications, and summarizes any recent policy updates impacting parenteral azathioprine claims processing. It also clarifies coding attributes tied to service lines and typical clinical settings. Data not available in the input is explicitly noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ7501HCPCS Level IIazathioprineparenteral-medicationinfusion-therapyoutpatient-pharmacydrug-codingimmunosuppressionmedication-administration

Billing Code Overview

HCPCS Level II code J7501 represents Azathioprine, parenteral, 100 mg. This code denotes the provision of azathioprine administered by injection or infusion for systemic immunosuppression.

Service Type: Parenteral medication administration

Typical Site of Service: Hospital outpatient departments, infusion centers, outpatient clinics, and other settings where parenteral therapies are delivered.

Clinical & Coding Specifications

Clinical Context

A typical patient receiving J7501 (Azathioprine, parenteral, 100 mg) is an adult or adolescent with an autoimmune or inflammatory condition requiring immunosuppressive therapy when oral administration is not feasible or during an initial inpatient loading period. Common clinical scenarios include a patient admitted for a severe flare of ulcerative colitis or Crohn disease who cannot tolerate oral medications due to nausea, vomiting, or concern for malabsorption; a renal transplant recipient in the early postoperative period requiring parenteral immunosuppression while oral intake is limited; or a patient with severe rheumatoid arthritis or systemic lupus erythematosus requiring temporary parenteral therapy.

The workflow typically involves:

Referral or admission with a documented indication for azathioprine.
Physician orders the parenteral formulation as J7501 with dose calculated by weight and adjusted for renal function and concurrent therapies.
Pharmacy verifies the order, prepares the appropriate volume for a 100 mg vial, and performs any necessary compounding under sterile conditions.
Nursing obtains informed consent as required by facility policy, verifies patient identity and allergies, establishes IV access, and administers the medication per protocol, monitoring for hypersensitivity, myelosuppression, hepatotoxicity, and acute infusion reactions.
Laboratory monitoring (CBC, hepatic panel) is ordered at baseline and at regular intervals after initiation or dose changes.
Documentation in the medical record includes indication, dose, lot number, administration time, site, patient tolerance, and any adverse events.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier	Use when no modifier applies and billing is for standard single-service parenteral medication administration.
`22`	Increased procedural services	Use when unusually extensive additional work is documented related to medication administration beyond routine preparation/administration (rare for single-dose parenteral drug).
`23`	Unusual anesthesia	Not typically applicable to `J7501`; use only if unusual anesthesia is required and documented.
`52`	Reduced services	Use when the full service was partially reduced or not completed as documented.
`53`	Discontinued procedure	Use when medication administration was started but discontinued due to patient intolerance or adverse reaction.
`62`	Two surgeons	Not commonly used for drug billing; include only if two qualified practitioners are required and documented for administration in a surgical setting.
`78`	Return to operating room	Not ordinarily applicable to parenteral drug billing; apply only when the drug administration is related to a subsequent intraoperative procedure.
`80`	Assistant surgeon	Rarely applicable; use when an assistant surgeon performs a component tied to the drug administration during surgery.
`JW`	Drug discarded/amount wasted	Use when a portion of the single-use vial is discarded and payer requires reporting of wasted drug.
`QK`	Medical direction of two or more CRNAs by a physician	Use only if specific anesthesia billing rules apply alongside drug administration.
`QX`	CRNA service; with medical direction by a physician	Applicable only in anesthesia-related scenarios.
`QY`	Medical direction of one CRNA by an anesthesiologist	Applicable only in anesthesia-related scenarios.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services	Use when an advanced practice provider administers the drug according to state scope and payer rules.
`JW`	Drug amount discarded, not administered to any patient	Use when documenting and billing for the full vial but noting discarded portion per payer policy.

Taxonomy Code	Specialty	Notes
`207RN0000X`	Registered Nurse	Primary clinicians administering parenteral azathioprine in inpatient and outpatient infusion settings.
`207T00000X`	Transplant Coordinator	Common in transplant programs managing immunosuppressive therapy and monitoring.
`207L00000X`	Clinical Pharmacist	Medication verification, preparation, dosing checks, drug interaction review.
`207P00000X`	Physician (General Internal Medicine)	Prescribing and oversight for medical inpatients and complex autoimmune cases.
`2080P0207X`	Rheumatology	Prescribing specialty for autoimmune diseases often managing azathioprine therapy.

ICD-10 Code	Description	Clinical Relevance
`K51.90`	Ulcerative colitis, unspecified, without complications	Azathioprine is used for maintenance therapy in moderate to severe ulcerative colitis or steroid-sparing therapy.
`K50.90`	Crohn's disease, unspecified, without complications	Azathioprine is used for induction/maintenance of remission in Crohn disease when immunosuppression is indicated.
`M06.9`	Rheumatoid arthritis, unspecified	Azathioprine is an immunosuppressive option for refractory rheumatoid arthritis under specialist management.
`M32.9`	Systemic lupus erythematosus, unspecified	Azathioprine can be used for maintenance therapy in systemic lupus affecting major organs.
`T86.10`	Kidney transplant failure, unspecified	Azathioprine is used as part of transplant immunosuppression regimens; dosing and route vary based on protocol.
`D72.8`	Other specified disorders of white blood cells	Monitoring is critical because azathioprine can cause myelosuppression; use when documenting baseline or adverse effects.

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, therapeutic, prophylactic, or diagnostic; initial, up to 1 hour	May be billed for the initial infusion time when parenteral azathioprine is administered and infusion time meets CPT definitions.
`96366`	Intravenous infusion, each additional hour	Use when infusion of the medication extends beyond the initial hour and documentation supports additional hourly infusion.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Use if azathioprine is administered via IM or SC route in settings where injectable administration is reported outside IV infusion codes.
`36415`	Collection of venous blood by venipuncture	Billed for required laboratory monitoring (CBC, hepatic panel) associated with initiating or continuing azathioprine.
`96360`	Intravenous infusion, hydration; initial, up to 1 hour	May be used when concurrent IV hydration is provided at the time of medication administration.

OpenPayer